Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

277 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Maschio G, et al. Among authors: mann jf. N Engl J Med. 1996 Apr 11;334(15):939-45. doi: 10.1056/NEJM199604113341502. N Engl J Med. 1996. PMID: 8596594 Clinical Trial.
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Mann JF, et al. Ann Intern Med. 2001 Apr 17;134(8):629-36. doi: 10.7326/0003-4819-134-8-200104170-00007. Ann Intern Med. 2001. PMID: 11304102 Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. Among authors: mann jf. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators. Mann JFE, et al. N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011. N Engl J Med. 2017. PMID: 28854085 Clinical Trial.
Effect of telmisartan on renal outcomes: a randomized trial.
Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S; TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Mann JF, et al. Ann Intern Med. 2009 Jul 7;151(1):1-10, W1-2. doi: 10.7326/0003-4819-151-1-200907070-00122. Epub 2009 May 18. Ann Intern Med. 2009. PMID: 19451556 Clinical Trial.
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators. Mann JF, et al. Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2. Lancet. 2008. PMID: 18707986 Clinical Trial.
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Wanner C, et al. Among authors: mann jf. N Engl J Med. 2005 Jul 21;353(3):238-48. doi: 10.1056/NEJMoa043545. N Engl J Med. 2005. PMID: 16034009 Clinical Trial.
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Among authors: mann jf. N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463. N Engl J Med. 2015. PMID: 26630142 Clinical Trial.
Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.
Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S. Mann JF, et al. Am J Cardiovasc Drugs. 2002;2(3):157-62. doi: 10.2165/00129784-200202030-00003. Am J Cardiovasc Drugs. 2002. PMID: 14727978 Review.
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Weber MA, Williams B, Yusuf S. Böhm M, et al. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7. Epub 2017 Apr 5. Lancet. 2017. PMID: 28390695
277 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback